The Food and Drug Administration has approved the first generic versions of the anti-HIV medication AZT, a move that could reduce the expense for people in the United States being treated for the disease. AZT, an antiretroviral drug that is also known as zidovudine or by its brand name Retrovir, helps prevent HIV from reproducing in the body. It is often used in combination with other medications to treat an HIV infection.
Generic versions of the drug have previously been unavailable in the United States because patent or market exclusivity restrictions prevented them from being marketed. Now that the patent expired on Saturday, September 17, versions of the drug manufactured by Roxane Laboratories of Columbus, Ohio; Ranbaxy Laboratories Ltd. of New Delhi, India; and Aurobindo Pharma Ltd. of Hyderabad, India, have been approved by the FDA to go on the U.S. market.
“These approvals will now allow those infected with HIV more access to these lifesaving drugs within our country,” said Mike Leavitt, secretary of the Department of Health and Human Services, in a statement. (AP)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.